trumprx glp 1 HR leaders hesitant to add GLP-1 coverage even after deal The Trump administration launched its

Additionally, over one third of the exposures were not followed to a definitive outcome whether due to follow-up being deemed unnecessary or the patient being lost to follow up

A randomised trial of GHRH analogues in older adults showed significant lean mass gains versus placebo over 26 weeks, alongside reductions in truncal fat.4 2

The cohort study, which analysed data from 125,474 adults with overweight or obesity, found that 46.5% of patients with Type 2 diabetes and 64.8% of those without the condition discontinued GLP-1 RAs within one year of starting treatment

These facts are in accordance with the perspective of this review which suggests the central and nuclear role of IGF-1 in metabolism

Below are some key interactions between GLP-1 medications and other diabetes treatments